Oxytrol (oxybutynin transdermal system)

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)

July 2015

Summary View


Central Nervous System Effects
  • *Addition of the terms “hallucinations” and “confusion”


Postmarketing Experience
  • *Addition of “hallucinations” and “confusion” 


January 2011

Summary View


  • Angioedema requiring hospitalization and emergency medical treatment has occurred with the first or subsequent doses of oral oxybutynin. In the event of angioedema, oxybutynin-containing products should be discontinued and appropriate therapy promptly provided.


Information for Patients
  • Patients should be informed that angioedema has been reported with oral oxybutynin use. Patients should be advised to promptly discontinue oxybutynin therapy and seek immediate medical attention if they experience symptoms consistent with angioedema 

Page Last Updated: 08/14/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English